Publicaciones en las que colabora con JAVIER PUENTE VÁZQUEZ (26)

2015

  1. A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer

    Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 330-338

  2. New Challenges in Kidney Cancer Management: Integration of Surgery and Novel Therapies

    Current Treatment Options in Oncology, Vol. 16, Núm. 3

  3. Renal cell cancer metastases to esophagus and stomach successfully treated with radiotherapy and pazopanib

    Anti-Cancer Drugs, Vol. 26, Núm. 1, pp. 112-116

2013

  1. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice

    Oncology (Switzerland), Vol. 84, Núm. 5, pp. 255-264

  2. Role of bevacizumab as continued maintenance in non-small cell lung cancer

    Cancer and Chemotherapy Reviews, Vol. 8, Núm. 3, pp. 129-137

  3. Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: Efficacy and safety data according to liver function

    Clinical and Translational Oncology, Vol. 15, Núm. 2, pp. 146-153

2012

  1. Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers

    Journal of Cancer Research and Clinical Oncology, Vol. 138, Núm. 5, pp. 867-875

2011

  1. Analysis of the oxidative damage repair genes NUDT1, OGG1, and MUTYH in patients from mismatch repair proficient HNPCC families (MSS-HNPCC)

    Clinical Cancer Research, Vol. 17, Núm. 7, pp. 1701-1712

  2. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

    Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136

  3. Optimizing first-line treatment in non-small cell lung cancer with bevacizumab

    Cancer and Chemotherapy Reviews, Vol. 6, Núm. 1, pp. 28-36

  4. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review

    Clinical and Translational Oncology, Vol. 13, Núm. 2, pp. 121-132

  5. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine- radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer

    Anti-Cancer Drugs, Vol. 22, Núm. 2, pp. 185-190

2010

  1. Breast cancer: Complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma

    Anti-Cancer Drugs, Vol. 21, Núm. SUPPL.1

  2. Celecoxib in a 12-year-old boy with familial adenomatous polyposis

    International Journal of Clinical Pharmacology and Therapeutics, Vol. 48, Núm. 3, pp. 230-232

  3. Practical prognostic index for patients with metastatic recurrent breast cancer: Retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register

    Breast Cancer Research and Treatment, Vol. 122, Núm. 2, pp. 591-600

2009

  1. Circulating tumor cells in metastatic breast cancer: Timing of blood extraction for analysis

    Anticancer Research, Vol. 29, Núm. 10, pp. 4185-4187

  2. Second-line therapy for advanced pancreatic cancer: A review of the literature and future directions

    Cancer Treatment Reviews, Vol. 35, Núm. 8, pp. 676-684

2008

  1. Circulating tumor cells in colorectal cancer: Correlation with clinical and pathological variables

    Annals of Oncology, Vol. 19, Núm. 5, pp. 935-938

  2. Irinotecan in the treatment of elderly patients with advanced colorectal cancer

    Critical Reviews in Oncology/Hematology, Vol. 68, Núm. 3, pp. 250-255

  3. Risk-reduction surgery in BRCA mutation carriers in a Spanish population: Adherence and results

    Clinical and Translational Oncology, Vol. 10, Núm. 10, pp. 660-664